Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early IVIg Plus Standard Therapy for High-Risk Severe Community-Acquired Pneumonia
ChiCTR2400090211Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in community-acquired pneumonia (CAP) comparing IVIg + standard therapy with Placebo + standard therapy (2 arms). Primary endpoint: All-cause mortality at 7 days. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
immune globulin
03
Conditions
community-acquired pneumonia (CAP)
Beyond the preview
Go deeper on ChiCTR2400090211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090211.